Jefferies Group LLC Aerie Pharmaceuticals Inc Transaction History

Jefferies Group LLC

  • $10.2 Billion
  • Q3 2022

A detailed history of Jefferies Group LLC transactions in Aerie Pharmaceuticals Inc stock. As of the latest transaction made, Jefferies Group LLC holds 2,361,000 shares of AERI stock, worth $0. This represents 0.35% of its overall portfolio holdings.

Number of Shares
2,361,000
Previous 2,361,000 -0.0%
Holding current value
$0
Previous $17.7 Million 101.73%
% of portfolio
0.35%
Previous 0.17%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$4.95 - $9.16 $79,051 - $146,285
-15,970 Reduced 0.67%
2,361,000 $17.7 Million
Q1 2022

Sep 21, 2023
SELL
$5.64 - $9.8 $84,600 - $147,000
-15,000 Reduced 0.63%
2,361,000 $21.5 Million
Q1 2022

May 16, 2022
SELL
$5.64 - $9.8 $68,813 - $119,569
-12,201 Reduced 0.51%
2,376,970 $21.5 Million
Q4 2021

Sep 21, 2023
BUY
$7.02 - $13.33 $105,300 - $199,950
15,000 Added 0.64%
2,376,000 $16.7 Million
Q4 2021

Feb 14, 2022
BUY
$7.02 - $13.33 $16.8 Million - $31.8 Million
2,389,171 New
2,389,171 $16.7 Million
Q3 2020

Nov 13, 2020
SELL
$10.46 - $14.46 $261,500 - $361,500
-25,000 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$12.0 - $16.13 $300,000 - $403,250
25,000 New
25,000 $369,000
Q1 2020

May 15, 2020
SELL
$11.84 - $25.52 $1.21 Million - $2.61 Million
-102,077 Closed
0 $0
Q4 2019

Feb 13, 2020
BUY
$17.72 - $25.1 $1.81 Million - $2.56 Million
102,077 New
102,077 $2.47 Million
Q3 2018

Nov 14, 2018
SELL
$56.15 - $73.9 $78,610 - $103,460
-1,400 Closed
0 $0
Q2 2018

Aug 14, 2018
BUY
$47.85 - $70.45 $66,990 - $98,630
1,400 New
1,400 $95,000

Others Institutions Holding AERI

# of Institutions
3
Shares Held
2.4M
Call Options Held
0
Put Options Held
0
View Full List

About AERIE PHARMACEUTICALS INC

AERI Quotes by TradingView
  • Ticker AERI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,390,500
  • Description
  • Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...
More about AERI
Track This Portfolio

Track Jefferies Group LLC Portfolio

Follow Jefferies Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email